What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs?

Milenkovic, Uros and Ilg, Marcus M. and Cellek, Selim and Albersen, Maarten (2019) What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs? Expert Opinion on Emerging Drugs, 24 (1). pp. 1-4. ISSN 1472-8214

[img] Text
Accepted Version
Restricted to Repository staff only until 19 March 2020.
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (52kB) | Request a copy
Official URL: https://doi.org/10.1080/14728214.2019.1591370

Abstract

Finding novel medical treatment for Peyronie’s disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways. Focusing on a single target during antifibrotic drug development has not led to the development of many efficacious drugs, especially in PD. Inhibiting one cog in this large machinery usually leads to activation of compensatory mechanisms.Expert opinion: Novel strategies in drug discovery such as phenotypical drug screening and gene expression profiling technologies could provide a solution for this impasse

Item Type: Journal Article
Keywords: Peyronie’s disease, medical treatment, phenotypical drug screening, extracellular matrix, macrophages, myofibroblasts
Faculty: Faculty of Health, Education, Medicine & Social Care
Depositing User: Ian Walker
Date Deposited: 19 Mar 2019 16:04
Last Modified: 14 Nov 2019 16:08
URI: http://arro.anglia.ac.uk/id/eprint/704181

Actions (login required)

Edit Item Edit Item